Your session is about to expire
← Back to Search
Diagnostic Test
Enhanced Monitoring for Atrial Fibrillation (CATCH-AF Trial)
N/A
Waitlist Available
Led By Markus Sikkel, MD
Research Sponsored by Victoria Cardiac Arrhythmia Trials
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age >18
Be older than 18 years old
Must not have
Previous diagnosis of atrial fibrillation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
Summary
This trial is investigating whether the Kardia Mobile monitoring device is a superior strategy for diagnosing Atrial Fibrillation (AF) in comparison to normal ambulatory monitoring with a 24-hour Holter monitor.
Who is the study for?
This trial is for adults over 18 who have symptoms like palpitations or shortness of breath, which could be due to an irregular heartbeat. They must not have been diagnosed with atrial fibrillation before but should have at least one stroke risk factor according to the CHADS2 score.Check my eligibility
What is being tested?
The study compares two ways of diagnosing Atrial Fibrillation: using a Kardia Mobile device continuously when symptoms occur versus a standard 24-hour Holter monitor. Participants are randomly assigned to one of these monitoring methods.See study design
What are the potential side effects?
There are generally no side effects associated with using either the Kardia Mobile or Holter monitoring devices as they are non-invasive tools used to record heart activity.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am older than 18.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been diagnosed with atrial fibrillation before.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Time to atrial fibrillation diagnosis compared between arms as analysed by Kaplan-Meier survival curves
Trial Design
2Treatment groups
Active Control
Group I: Enhanced MonitoringActive Control2 Interventions
Kardia/AliveCor monitoring with additional Holter monitoring as needed
Group II: Standard of CareActive Control1 Intervention
Holter monitoring
Find a Location
Who is running the clinical trial?
Victoria Cardiac Arrhythmia TrialsLead Sponsor
1 Previous Clinical Trials
100 Total Patients Enrolled
Markus Sikkel, MDPrincipal InvestigatorVictoria Cardiac Arrhythmia Trials Inc.
Share this study with friends
Copy Link
Messenger